Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, NuPulseCV is raising $19,999,999.00 in new funding. Sources indicate as part of senior management President, Sonna Patel-Raman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NuPulseCV

The iVAS medical device (ambulatory counterpulsation) by NuPulseCV is being evaluated through a clinical trial as an option for patients who have advanced heart failure and who are no longer benefiting from guideline directed medical therapies.  The iVAS is a less invasive option that may help address heart failure symptoms (NYHA III and IV), which may allow a heart failure patient to return to daily activities.

To learn more about NuPulseCV, visit http://nupulsecv.com/

Contact:
Sonna Patel-Raman, President
301-768-0870
sonna@nupulsecv.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved